Stay updated on Empagliflozin vs Placebo in HF: Arrhythmic Events Clinical Trial
Sign up to get notified when there's something new on the Empagliflozin vs Placebo in HF: Arrhythmic Events Clinical Trial page.

Latest updates to the Empagliflozin vs Placebo in HF: Arrhythmic Events Clinical Trial page
- Check5 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Notably, the information regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference0.9%
- Check12 days agoNo Change Detected
- Check20 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been pushed back from June 2025 to July 2025.SummaryDifference0.7%
- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check41 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check70 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check84 days agoChange DetectedThe webpage has been updated to reflect a new study design involving empagliflozin, focusing on its effects on arrhythmias in diabetic patients with heart failure. Key details include the study's crossover design and the involvement of collaborators, specifically Boehringer Ingelheim.SummaryDifference47%
Stay in the know with updates to Empagliflozin vs Placebo in HF: Arrhythmic Events Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Empagliflozin vs Placebo in HF: Arrhythmic Events Clinical Trial page.